Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Juno Therapeutics (JUNO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 8,148,313
  • Shares Outstanding, K 114,170
  • Annual Sales, $ 79,360 K
  • Annual Income, $ -245,580 K
  • 36-Month Beta 2.32
  • Price/Sales 66.32
  • Price/Cash Flow N/A
  • Price/Book 6.94

Price Performance

See More
Period Period Low Period High Performance
1-Month
43.30 +56.61%
on 12/20/17
74.35 -8.80%
on 01/18/18
+24.06 (+54.99%)
since 12/19/17
3-Month
42.25 +60.50%
on 10/26/17
74.35 -8.80%
on 01/18/18
+24.41 (+56.24%)
since 10/19/17
52-Week
19.07 +255.58%
on 01/24/17
74.35 -8.80%
on 01/18/18
+48.02 (+242.65%)
since 01/19/17

Most Recent Stories

More News
Juno Therapeutic Shares Up 39.0% Since SmarTrend's Buy Recommendation (JUNO)

SmarTrend identified an Uptrend for Juno Therapeutic (NASDAQ:JUNO) on January 5th, 2018 at $48.79. In approximately 2 weeks, Juno Therapeutic has returned 38.98% as of today's recent price of $67.81.

JUNO : 67.81 (-4.99%)
JUNO THERAPEUTICS INVESTIGATION by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Juno Therapeutics, Inc. - JUNO

Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that KSF has commenced an investigation into Juno...

JUNO : 67.81 (-4.99%)
Gilead Collaborates with Pfizer for Yescarta Combo Study

Kite, a Gilead Company (GILD), announced that it inked a clinical trial collaboration with Pfizer, for combination study.

NVS : 86.94 (+0.61%)
GILD : 80.98 (-0.23%)
PFE : 36.94 (-0.14%)
JUNO : 67.81 (-4.99%)
Juno Hits 52-Week High on Celgene's Rumored Buyout Interest

Juno Therapeutics, Inc.'s (JUNO) shares hit a 52 week high on rumors of the company being acquired by Celgene Corporation.

CELG : 102.65 (+0.91%)
NVS : 86.94 (+0.61%)
GILD : 80.98 (-0.23%)
JUNO : 67.81 (-4.99%)
Company News For Jan 18, 2018

Companies In The News are: TIF,CSX,JUNO,CELG,FAST

TIF : 107.77 (-0.26%)
CELG : 102.65 (+0.91%)
CSX : 57.49 (-0.96%)
FAST : 53.74 (+0.85%)
JUNO : 67.81 (-4.99%)
M&A Waves Pushing Biotech ETFs Higher

The new tax legislation has enticed U.S. companies to bring offshore cash back home, sparking waves of mergers and acquisitions.

BBC : 31.26 (+1.66%)
PBE : 50.44 (+1.35%)
CELG : 102.65 (+0.91%)
CNCR : 26.56 (+1.90%)
FBT : 133.08 (+0.77%)
JUNO : 67.81 (-4.99%)
Juno Therapeutics Reaches Analyst Target Price

In recent trading, shares of Juno Therapeutics Inc have crossed above the average analyst 12-month target price of $57.18, changing hands for $69.25/share. When a stock reaches the target an analyst...

JUNO : 67.81 (-4.99%)
Novartis sBLA for CAR-T Therapy Kymriah Accepted by FDA

Novartis (NVS) gets a significant boost with the FDA approval of CAR-T Therapy Kymriah and the company is now looking to expand the therapy's label.

CELG : 102.65 (+0.91%)
NVS : 86.94 (+0.61%)
GILD : 80.98 (-0.23%)
JUNO : 67.81 (-4.99%)
3 Top-Ranked Drug Stocks that are Broker Favorites

With the pharma and biotech sector performing well in 2017, here is a look at three drug stocks including Vertex (VRTX) that are broker favorites.

CELG : 102.65 (+0.91%)
COLL : 23.38 (+15.69%)
VRTX : 157.97 (+0.50%)
SNDX : 10.17 (+6.16%)
NVS : 86.94 (+0.61%)
GILD : 80.98 (-0.23%)
JUNO : 67.81 (-4.99%)
M&A Waves Pushing Biotech ETFs Higher

The new tax legislation has enticed U.S. companies to bring offshore cash back home, sparking waves of mergers and acquisitions.

BBC : 31.26 (+1.66%)
PBE : 50.44 (+1.35%)
CELG : 102.65 (+0.91%)
CNCR : 26.56 (+1.90%)
FBT : 133.08 (+0.77%)
JUNO : 67.81 (-4.99%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More

Business Summary

Juno Therapeutics, Inc. is a biopharmaceutical company. The Company develops cellular immunotherapies based on two platforms - Chimeric Antigen Receptors (CARs) and T Cell Receptors (TCRs) technologies. Its clinical CD19 product candidates include JCAR015 that is in Phase I clinical trials for adult...

See More

Key Turning Points

2nd Resistance Point 73.92
1st Resistance Point 70.87
Last Price 67.81
1st Support Level 65.57
2nd Support Level 63.32

See More

52-Week High 74.35
Last Price 67.81
Fibonacci 61.8% 53.23
Fibonacci 50% 46.71
Fibonacci 38.2% 40.19
52-Week Low 19.07

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.